CIRCULAR consortium – AFIP foundation

An international atrial fibrillation network

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting millions of people worldwide. Unfortunately, AF is still difficult to diagnose and treat, due to a lack of knowledge about the molecular mechanisms that cause AF. Current treatments for AF are based on a ‘ one-size-fits-all ‘ approach and do not prevent the progression of recurrent episodes to permanent AF.

In addition, it is challenging to determine the stage of AF. Therefore, AF progresses over time and causes an enormous physical, psychological, social, and economic burden. Recognizing the need for progress in AF research, Prof. Dr. Bianca Brundel leads the groundbreaking project ‘CIRCULAR’, part of the international atrial fibrillation network. This project, funded by the Netherlands Organization for Scientific Research (NWO), NWA-ORC program, aims to unravel the underlying triggers of AF, develop innovative diagnostic tools, and pioneer new therapeutic strategies.

On the way to personalized treatments developed together with patients

Using citizen science, patients have already identified five major triggers for AF. Together with patients, researchers, and health professionals, the CIRCULAR consortium aims to explore these triggers further. Moreover, experimental research aims to build the molecular human AF atlas, which serves for new drug discovery and biomarker research. Through co-creation with patients, new treatments are tested in clinical trials. The approach is unique because it combines animal-free advanced systems and circular research for tailor-made solutions for the patient. The AFIP Foundation has previously set up clinical studies together with (physician) researchers, including the L-glutamine study and the AF-Energy study.

Causes of atrial fibrillation

Causes of atrial fibrillation can differ per person. Since the treatment of atrial fibrillation is currently focused on a one-size-fits-all approach, the treatment is not equally effective for everyone. The most common causes of atrial fibrillation are divided into the following categories:

aging
a western lifestyle
genetic causes

Learn more about the causes of AF

The CIRCULAR consortium

The CIRCULAR consortium aims to reduce the burden of AF by investigating how triggers for AF result in molecular and electrical dysfunction. This is tested in co-creation with people with experience in AF and innovative animal-free technologies. The findings are used to discover effective treatments and diagnostics. To achieve this, the AFIP Foundation co-creates scientific and social solutions with patients, researchers, and health professionals.

Through collaboration with valued partners and a patient-centered approach, the CIRCULAR project aims to transform the landscape of AF treatment and improve the lives of those affected.

Building blocks of the CIRCULAR consortium

AFIP foundation

The AFIP Foundation plays a central role in the CIRCULAR project. This foundation acts as a catalyst for collaboration between AF patients, healthcare professionals, and researchers. AFIP aims to bridge the gap between scientific progress and patient care, facilitating the development and implementation of innovative treatments for AF. AFIP has established a citizen science foundation with AF patients being involved in the creation of studies.

Understanding bioelectrical dysfunction

A major focus of the CIRCULAR project is understanding the complex mechanisms that drive AF. The team found that bioelectrical dysfunction plays a crucial role in the development and progression of AF. We hope to discover new therapeutic targets and interventions by investigating the electrical and contractile dysfunction caused by damage to atrial tissue.

Biomarkers for early detection

Early diagnosis of AF is crucial for effective management and prevention of complications. Thanks to previous research, the CIRCULAR project has made significant progress in identifying blood-based biomarkers that can improve the detection of AF. These biomarkers have the potential to revolutionize screening methods, enabling proactive intervention and personalized treatment plans.

Patient-funded research

The consortium recognizes the importance of patient involvement in the research process and actively participates in patient-funded initiatives. For example, the GGA Atrial Fibrillation Trial is investigating preventive measures for AF, specifically focusing on the use of Geranyl Geranyl Acetone (GGA) to prevent the onset of postoperative AF. By involving patients and their families, this study aims to improve patient outcomes and increase understanding of AF prevention strategies. This study is in collaboration with the StopAfib.org foundation and IXA.

Unraveling protein homoeostasis mechanisms

The CIRCULAR project places a strong emphasis on investigating protein homeostasis and the protein quality control system in relation to AF. The research group conducts in-depth studies to unravel the molecular mechanisms underlying AF pathogenesis. By deciphering these complex mechanisms, the team hopes to develop personalized diagnostic tools and mechanism-based therapies that address AF at its core.

Collaborations and partnerships

To achieve our ambitious goals, CIRCULAR collaborates with renowned researchers and institutions around the world. These partnerships promote a multidisciplinary approach to AF research, combining expertise from different domains such as cardiology, genetics, biochemistry, and biomedical engineering. Through these collaborations, the CIRCULAR project benefits from diverse perspectives and accelerates discoveries.